| CFG |
Report |
EPS |
BEAT |
pred ~$1.26 vs. cons $1.24 |
MEDIUM |
| CFG |
Report |
Noninterest income / Fees (Capital Markets-led) |
BEAT |
pred ~+6.5% YoY vs. cons guided +3-5% QoQ/consensus ~$620M |
MEDIUM |
| CFG |
Report |
Net Interest Income (NII) |
IN-LINE |
pred ~+3.5% QoQ vs. cons/guide +3% to 4% QoQ |
HIGH |
| CFG |
Guide |
Q3'26 NII growth guide |
UNCHANGED |
guide ~+2% to 3% QoQ vs. cons ~+3% QoQ (Q3 2026) |
LOW |
| CFG |
Guide |
FY'26 fee growth guide (6-8%) |
UNCHANGED |
guide ~6% to 8% FY vs. cons ~7% FY (FY2026) |
MEDIUM |
| CFG |
Guide |
4Q'26 NIM target (3.22-3.28%) |
UNCHANGED |
guide ~3.22% to 3.28% vs. cons ~3.25% (4Q 2026) |
MEDIUM |
| CFG |
Guide |
Capital return / buyback pace post-stress test |
BETTER |
guide ~$300M-$350M buyback vs. cons/prior ~$225M (Q3 2026) |
MEDIUM |
| CFG |
Guide |
CET1 ratio target |
UNCHANGED |
guide ~10.5% to 10.6% vs. cons ~10.5% (Q2 2026) |
MEDIUM |
| CFG |
Return |
Day-1 residual (stock − beta × S&P 500) |
+0.6% |
— |
LOW |
| CFG |
Return |
5-day cumulative residual |
-0.8% (FADE) |
Stock is already up ~10% into the print and at all-time highs with a high bar priced in (56.9% 1Y return, 16.7x P/E); a modest EPS/fee beat with unchanged (not raised) NII/NIM/fee guidance for Q3-Q4 implies decelerating sequential growth off tougher comps, so initial pop from the beat and capital-return optimism likely fades over the week as analysts trim out-quarter NII/fee growth assumptions back toward the reaffirmed (not raised) ranges rather than extrapolating Q2's pace. |
LOW |